Oppenheimer remains bullish on Sarepta Therapeutics (SRPT) following KOL fireside chat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
UBS Upgrades Sarepta Therapeutics (SRPT) to Buy on expected accelerated approval for '9001
December 16, 2022 6:47 AM EST(Updated - December 16, 2022 8:37 AM EST)
UBS analyst Colin Bristow upgraded Sarepta Therapeutics (NASDAQ: SRPT) from Neutral to Buy with a price target of $158.00 (from $100.00), saying they expect '9001 to get accelerated FDA approval.
The analyst commented, "We are upgrading SRPT to a Buy rating and... More
